What are the latest funding news in the biotechnology market? (September 2026)
Download our beautiful pitch about the biotechnology market
In our biotechnology market deck, you will find everything you need to understand the market
Biotechnology funding activity remained broad in late August and early September 2026, spanning clinical therapeutics, diagnostics, and life-science research infrastructure.
The 12 disclosed financings in this tracker represented roughly $403M in headline deal value, although part of that total included prior SAFE proceeds and contingent warrant funding.
And if you want to better understand this new industry, you can download our pitch covering the biotechnology market.
Insights
- These 12 biotechnology funding deals represented roughly $403M in headline value, but the comparable upfront or newly closed capital was closer to $358M after excluding Airway’s earlier SAFE and Quoin’s potential warrant proceeds.
- AusperBio’s $120M Series C accounted for almost 30% of the period’s headline biotechnology funding, showing how later-stage hepatitis B programs can dominate a short funding window.
- The four $50M-plus headline financings, AusperBio, Quoin Pharmaceuticals, Airway Therapeutics, and Network Bio, made up about 67% of the total value tracked in this biotechnology market snapshot.
- Therapeutics companies accounted for seven of the 12 deals and nearly 70% of headline funding, led by nucleic-acid medicines, rare-disease programs, biologics, and protein-degradation platforms.
- Life-science research tools attracted $113M across Adaptyv Biosystems, Outer Bio, and Network Bio, highlighting investor interest in the experimental-data infrastructure behind modern drug discovery.
- Every company in the tracker had an undisclosed valuation, a reminder that announced biotechnology financings often reveal round size and investors without providing a usable price benchmark.
- Five clearly clinical or late-clinical companies raised about $259M in headline capital, reflecting the large financing needs attached to regulatory studies, manufacturing, and commercial preparation.
- Seven companies had a primary United States focus, while the rest added exposure to China, Switzerland, Germany, Israel, and global biopharma markets.
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Summary table of the latest funding deals in the biotechnology market as of September 2026
We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes.
We include biopharma R&D and therapeutics, including biologics, cell and gene therapies, and vaccines, molecular diagnostics, and core life-science research tools and reagents used to generate and analyze biological data.
We exclude routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture or industrial bioapplications unless they are explicitly in scope for the analysis.
You can also read our detailed analysis to understand how funding activity in the biotechnology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the biotechnology market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Senticell | 1 September 2026 | About $7M | Seed | Molecular diagnostics & liquid biopsy |
| Convergen | 31 August 2026 | $15M | Seed+ | Targeted protein degradation therapeutics |
| EIT Pharma | 31 August 2026 | $35M | Series A | Infectious-disease therapeutics |
| Quoin Pharmaceuticals | 28 August 2026 | Up to $50M | Private placement | Rare-disease therapeutics |
| BioLineRx | 28 August 2026 | $3.75M | Registered direct offering & private placement | Oncology & rare-disease therapeutics |
| AusperBio | 27 August 2026 | $120M | Series C | Oligonucleotide therapeutics |
| Biomerica | 27 August 2026 | $2.23M | Private placement | Clinical diagnostics & life-science products |
| Adaptyv Biosystems | 26 August 2026 | $40M | Series A | Protein engineering & automated wet labs |
| Outer Bio | 26 August 2026 | $23M | Series B | Human tissue research & bioactive discovery |
| Airway Therapeutics | 25 August 2026 | $24M new cash, $50M total | Series E-2 | Respiratory biologics |
| Revier Therapeutics | 25 August 2026 | About $7M | Seed | Cardiometabolic therapeutics |
| Network Bio | 19 August 2026 | $50M | Venture financing | Biological data & life-science research tools |
All the latest funding deals in the biotechnology market as of September 2026
Senticell raised about $7M during the biotechnology funding period.
When was it?
Senticell announced its oversubscribed seed financing on 1 September 2026.
Who are they?
Senticell develops a liquid-biopsy platform that captures cancer-related nucleic-acid signals bound to red blood cells.
Geographical focus?
Senticell is based in the United States and is building its platform for oncology applications.
Why do we include them in the biotechnology market?
Senticell belongs in the biotechnology market because its liquid-biopsy technology is a molecular diagnostics platform for cancer detection and monitoring.
What is the company stage?
Senticell is a seed-stage company conducting clinical validation of its diagnostic platform.
How much did they raise?
Senticell raised a seed round approaching $7M, while its valuation was not publicly disclosed.
What round is it?
Senticell completed an oversubscribed seed round.
Why did they raise?
Senticell raised the capital to run oncology clinical studies and advance its RBC-based liquid-biopsy platform toward clinical and commercial use.
Convergen raised $15M during the biotechnology funding period.
When was it?
Convergen announced the Seed+ financing on 31 August 2026.
Who are they?
Convergen develops targeted protein degraders for neurodegenerative and other diseases linked to pathological protein aggregates.
Geographical focus?
Convergen operates from China while targeting global biopharma opportunities.
Why do we include them in the biotechnology market?
Convergen belongs in the biotechnology market because its TrimTAC platform develops precision therapeutics through targeted protein degradation.
What is the company stage?
Convergen is a preclinical company at the Seed+ stage.
How much did they raise?
Convergen raised $15M, and the company did not disclose a valuation.
What round is it?
Convergen completed a Seed+ financing led by MPCi.
Why did they raise?
Convergen raised the capital to advance its degrader platform, progress lead programs through IND-enabling work, and expand its pipeline.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
EIT Pharma raised $35M during the biotechnology funding period.
When was it?
EIT Pharma announced its Series A round on 31 August 2026.
Who are they?
EIT Pharma develops therapies for infectious diseases, including lonafarnib for chronic hepatitis D.
Geographical focus?
EIT Pharma is based in the United States and is preparing for global rare-disease and infectious-disease markets.
Why do we include them in the biotechnology market?
EIT Pharma belongs in the biotechnology market because it develops and commercializes biopharmaceutical therapies for high-unmet-need infectious diseases.
What is the company stage?
EIT Pharma is a late-stage clinical and pre-commercial biotechnology company.
How much did they raise?
EIT Pharma raised $35M, with no valuation disclosed in the public announcement.
What round is it?
EIT Pharma completed an oversubscribed Series A led by Propel Bio Partners.
Why did they raise?
EIT Pharma raised the capital to support late-stage development, manufacturing, FDA review activities, and commercial preparation for lonafarnib.
Quoin Pharmaceuticals announced up to $50M during the biotechnology funding period.
When was it?
Quoin Pharmaceuticals announced the private placement on 28 August 2026.
Who are they?
Quoin Pharmaceuticals develops therapeutic products for rare and orphan diseases, led by QRX003 for Netherton syndrome.
Geographical focus?
Quoin Pharmaceuticals is United States-focused and has planned commercial reach across major international rare-disease markets.
Why do we include them in the biotechnology market?
Quoin Pharmaceuticals belongs in the biotechnology market because it develops specialized biopharmaceutical treatments for underserved rare-disease patients.
What is the company stage?
Quoin Pharmaceuticals is a late clinical-stage public biotechnology company.
How much did they raise?
Quoin Pharmaceuticals received $30.8M upfront and may receive another $19.2M from warrant exercises, for up to $50M in total.
What round is it?
Quoin Pharmaceuticals completed a private placement financing.
Why did they raise?
Quoin Pharmaceuticals raised the capital to advance rare-disease clinical programs and extend its operating runway.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
BioLineRx raised $3.75M during the biotechnology funding period.
When was it?
BioLineRx announced the financing on 28 August 2026.
Who are they?
BioLineRx develops clinical-stage therapies for cancer and rare diseases.
Geographical focus?
BioLineRx operates across Israel, the United States, and global biopharma markets.
Why do we include them in the biotechnology market?
BioLineRx belongs in the biotechnology market because it advances novel therapeutic candidates through clinical development.
What is the company stage?
BioLineRx is a clinical-stage public biotechnology company.
How much did they raise?
BioLineRx raised $3.75M, and the financing valuation was not disclosed.
What round is it?
BioLineRx completed a registered direct offering alongside a concurrent private placement.
Why did they raise?
BioLineRx raised the funds to support clinical programs and general corporate working capital.
AusperBio raised $120M during the biotechnology funding period.
When was it?
AusperBio announced the Series C financing on 27 August 2026.
Who are they?
AusperBio develops oligonucleotide medicines for chronic hepatitis B, led by the clinical candidate AHB-137.
Geographical focus?
AusperBio operates across the United States and China while addressing the global hepatitis B market.
Why do we include them in the biotechnology market?
AusperBio belongs in the biotechnology market because it uses a proprietary oligonucleotide platform to create next-generation antiviral medicines.
What is the company stage?
AusperBio is a clinical-stage biopharmaceutical company in Series C development.
How much did they raise?
AusperBio raised $120M, while the company did not disclose its valuation.
What round is it?
AusperBio completed a Series C financing with a global life-science investor syndicate.
Why did they raise?
AusperBio raised the capital to advance AHB-137 toward potential commercialization and expand its next-generation hepatitis B pipeline.
In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
Biomerica raised $2.23M during the biotechnology funding period.
When was it?
Biomerica announced the private placement on 27 August 2026.
Who are they?
Biomerica develops, manufactures, and markets diagnostic products for clinical laboratories, point-of-care settings, and consumers.
Geographical focus?
Biomerica is headquartered in the United States and sells diagnostic products globally.
Why do we include them in the biotechnology market?
Biomerica belongs in the biotechnology market because its in-vitro diagnostic products help screen for and detect disease.
What is the company stage?
Biomerica is a commercial public diagnostics company with established products.
How much did they raise?
Biomerica raised $2.23M, and the company did not disclose a valuation.
What round is it?
Biomerica completed a private placement involving B. Riley, company executives, and board members.
Why did they raise?
Biomerica raised the capital to support operations, product commercialization, and working capital needs.
Adaptyv Biosystems raised $40M during the biotechnology funding period.
When was it?
Adaptyv Biosystems announced the Series A round on 26 August 2026.
Who are they?
Adaptyv Biosystems operates automated wet labs that test and validate protein designs generated by computational biology teams.
Geographical focus?
Adaptyv Biosystems is based in Switzerland and serves global life-science and protein-engineering customers.
Why do we include them in the biotechnology market?
Adaptyv Biosystems belongs in the biotechnology market because its automated experimental platform generates the biological data needed for protein engineering.
What is the company stage?
Adaptyv Biosystems is a commercial scale-up company at the Series A stage.
How much did they raise?
Adaptyv Biosystems raised $40M, with no valuation disclosed in the reviewed reporting.
What round is it?
Adaptyv Biosystems completed a Series A led by Highland Europe.
Why did they raise?
Adaptyv Biosystems raised the capital to expand automated lab capacity, grow its team, and increase access for protein-engineering customers.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Outer Bio raised $23M during the biotechnology funding period.
When was it?
Outer Bio announced its Series B financing on 26 August 2026.
Who are they?
Outer Bio combines living human skin tissue, automated screening, and machine learning to discover skin-health bioactives.
Geographical focus?
Outer Bio is based in the United States and is building a platform for global biotechnology and skin-health partners.
Why do we include them in the biotechnology market?
Outer Bio belongs in the biotechnology market because its human-tissue platform creates biological data for compound discovery and therapeutic research.
What is the company stage?
Outer Bio is a growth-stage biotechnology company expanding its platform and research operations.
How much did they raise?
Outer Bio raised $23M, while the company’s valuation was not publicly disclosed.
What round is it?
Outer Bio completed a Series B with backing from investors including Hawktail, Initialized, Lightspeed, and Wing.
Why did they raise?
Outer Bio raised the funding to grow laboratory automation, advance bioactive discovery programs, and expand its scientific team.
Airway Therapeutics closed $24M in new cash during the biotechnology funding period.
When was it?
Airway Therapeutics announced the Series E-2 close on 25 August 2026.
Who are they?
Airway Therapeutics develops biologic medicines for serious respiratory, inflammatory, and infectious diseases, led by zelpultide alfa.
Geographical focus?
Airway Therapeutics is United States-based and is developing respiratory medicines for global patient populations.
Why do we include them in the biotechnology market?
Airway Therapeutics belongs in the biotechnology market because zelpultide alfa is a recombinant human surfactant protein biologic.
What is the company stage?
Airway Therapeutics is a late clinical-stage biopharmaceutical company running a Phase 2b/3 program.
How much did they raise?
Airway Therapeutics closed $24M in new Series E-2 cash, bringing its total Series E financing to $50M including a previously raised $26M SAFE.
What round is it?
Airway Therapeutics completed a Series E-2 round with broad participation from existing investors.
Why did they raise?
Airway Therapeutics raised the capital to complete the Phase 2b portion of its zelpultide alfa study and fund related manufacturing work.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Revier Therapeutics raised about $7M during the biotechnology funding period.
When was it?
Revier Therapeutics announced its €6M seed financing on 25 August 2026.
Who are they?
Revier Therapeutics develops selective class IIa HDAC inhibitors for cardiometabolic diseases such as HFpEF and atherosclerotic cardiovascular disease.
Geographical focus?
Revier Therapeutics is based in Germany and is developing medicines for global cardiometabolic markets.
Why do we include them in the biotechnology market?
Revier Therapeutics belongs in the biotechnology market because it is creating targeted small-molecule therapies based on a novel disease-biology approach.
What is the company stage?
Revier Therapeutics is a seed-stage preclinical biotechnology company.
How much did they raise?
Revier Therapeutics raised €6M, or about $7M, and did not disclose a valuation.
What round is it?
Revier Therapeutics completed a seed round led by KHAN Technology Transfer Fund II.
Why did they raise?
Revier Therapeutics raised the funding to advance preclinical programs and build its scientific and clinical development functions.
Network Bio raised $50M during the biotechnology funding period.
When was it?
Network Bio launched with its $50M financing on 19 August 2026.
Who are they?
Network Bio builds disease-specific biological models from patient tissue, paired blood samples, and clinical outcome data.
Geographical focus?
Network Bio is United States-based and works with academic biobanks and biopharma partners serving global healthcare markets.
Why do we include them in the biotechnology market?
Network Bio belongs in the biotechnology market because it generates and analyzes human biological data for drug discovery and clinical development.
What is the company stage?
Network Bio is a newly launched growth-stage company building its dataset, research network, and biopharma partnerships.
How much did they raise?
Network Bio raised $50M, and the company did not disclose its valuation.
What round is it?
Network Bio announced a venture financing backed by Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital.
Why did they raise?
Network Bio raised the capital to expand patient-derived datasets, develop disease models, and support partnerships with biopharma companies.
Related blog posts
- How funding activity has changed in the biotechnology market
- How strong is fundraising in the biotechnology market right now?
- What are the key fundraising trends in the biotechnology market?
- What are the top startups in the biotechnology market?
- The startups that have raised the most funding in the biotechnology market
